Overview
Jean-Pol Detiffe is based in Charleroi and is the founder of OncoDNA, where he has been Chief Strategy and Innovation Officer and a board member of OncoDNA and Integragen since January 2021, having served as founder and chief executive from November 2012 to January 2021. In 2025 he founded Vicus Padel, and in September 2023 he co-founded OncoRNA. He has sat on the board of directors of Sambrinvest since January 2021 and on that of the Clinique Notre-Dame de Grâce since December 2020, and since January 2014 he has taught pharmacogenomics at the Université libre de Bruxelles as a hospital pharmacist.
Detiffe founded DNAVision SA in 2004 and led it as chief executive until February 2012, and he was a member of the board of BioWin, the Health Cluster of Wallonia, from 2009 to 2012. He began his career at Quality Assistance in 1997, working in business development, then as pharmacist director assistant and in biotechnology business development until December 2003.
He qualified as a pharmacist at the Université catholique de Louvain in 1995, where he also took an agregation in sciences and a bachelor in business administration at IAG, and completed studies as an industrial pharmacist at the Université libre de Bruxelles in 1999.
Career history
In the news
- Very proud to see our International User Group Meeting grow year after year. This third edition, held in the beautiful city of Valencia, was a tremendous success and a new milestone for OncoDNA. What started three years ago as an initiative to bring our customers together is gradually becoming a strong and truly engaged international community — a place where laboratories and oncology professionals can openly share their expertise, experiences, challenges and best practices. Our network is now approaching 100 laboratories
- From my first visit and collaboration in 2009, it has been incredible to witness the remarkable journey of MGI and BGI Genomics. 尹烨 A big thank you to the MGI and BGI teams for the warm welcome and the opportunity to visit your facilities. I am genuinely impressed by the scale of your operations, the pace of innovation, and the vision driving the future of sequencing. The continuous development of new sequencing technologies and solutions will help make high-quality genomic testing increasingly accessible and affordable for cancer
- Great work and poster Katya Mokretar congratulations to you and the Synnovis / Guy’s Hospital team. Impressive TAT of 2,5 days in routine for OncoDEEP all-in-one CGP solution, covering all key biomarkers such as SNV, CNV, MSI, TMB and HRD. Beyond the analytical performance, the real impact is for patients: faster results, more clinically relevant information from one assay. And also with a highly competitive price compared with alternative. Very proud to see OncoDNA technology supporting routine genomic medicine in such a strong
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.